Article
Drug resistance profiles of mutations in the RET kinase domain.
British journal of pharmacology - 1 Sept 2018
Liu Xuan, Shen Tao, Mooers Blaine H M, Hilberg Frank, Wu Jie
Abstract excerpt
BACKGROUND AND PURPOSE: Alterations in the tyrosine kinase enzyme RET are found in thyroid and lung cancer. While RET TK inhibitors (TKIs) are used to treat thyroid cancer and are in clinical trials for RET fusion-positive non-small cell lung cancer, the impact of mutations in the RET kinase domain on drug sensitivity is largely uncharacterized. EXPERIMENTAL APPROACH: We identified and analysed mutations in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.